1. Home
  2. RYTM vs CADE Comparison

RYTM vs CADE Comparison

Compare RYTM & CADE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • CADE
  • Stock Information
  • Founded
  • RYTM 2008
  • CADE 1876
  • Country
  • RYTM United States
  • CADE United States
  • Employees
  • RYTM N/A
  • CADE N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • CADE Major Banks
  • Sector
  • RYTM Health Care
  • CADE Finance
  • Exchange
  • RYTM Nasdaq
  • CADE Nasdaq
  • Market Cap
  • RYTM 6.4B
  • CADE 7.0B
  • IPO Year
  • RYTM 2017
  • CADE N/A
  • Fundamental
  • Price
  • RYTM $110.20
  • CADE $36.66
  • Analyst Decision
  • RYTM Strong Buy
  • CADE Buy
  • Analyst Count
  • RYTM 13
  • CADE 12
  • Target Price
  • RYTM $110.38
  • CADE $40.67
  • AVG Volume (30 Days)
  • RYTM 589.3K
  • CADE 2.4M
  • Earning Date
  • RYTM 11-04-2025
  • CADE 10-20-2025
  • Dividend Yield
  • RYTM N/A
  • CADE 3.01%
  • EPS Growth
  • RYTM N/A
  • CADE N/A
  • EPS
  • RYTM N/A
  • CADE 2.82
  • Revenue
  • RYTM $156,287,000.00
  • CADE $1,744,915,000.00
  • Revenue This Year
  • RYTM $46.14
  • CADE $17.44
  • Revenue Next Year
  • RYTM $63.37
  • CADE $11.03
  • P/E Ratio
  • RYTM N/A
  • CADE $12.95
  • Revenue Growth
  • RYTM 53.55
  • CADE 42.82
  • 52 Week Low
  • RYTM $45.91
  • CADE $25.22
  • 52 Week High
  • RYTM $113.91
  • CADE $40.23
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 69.35
  • CADE 44.09
  • Support Level
  • RYTM $97.97
  • CADE $35.49
  • Resistance Level
  • RYTM $113.91
  • CADE $39.76
  • Average True Range (ATR)
  • RYTM 3.77
  • CADE 1.19
  • MACD
  • RYTM 1.20
  • CADE -0.25
  • Stochastic Oscillator
  • RYTM 79.43
  • CADE 24.66

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About CADE Cadence Bank

Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.

Share on Social Networks: